Wacker acquires Scil Proteins Production
The transaction will create a leading microbial-based biopharmaceutical manufacturer
Wacker Biotech, the contract biomanufacturing subsidiary of German chemical company Wacker Chemie, has purchased Scil Proteins Production, a privately owned contract manufacturer of recombinant proteins based in Halle, Germany, from the sole shareholder, BioNet Ventures.
No financial details have been revealed. The transaction is expected to close at the beginning of 2014.
Under the terms of the agreement, Jena-based Wacker will acquire all assets of Scil Proteins Production, including its manufacturing site and patent portfolio.
The business of sister company Scil Proteins, including the Affilin discovery platform and its corresponding service portfolio of lead identification and lead optimisation services, is unaffected by the deal and remains in the sole ownership of BioNet Ventures.
'Integrating Scil Proteins Production into Wacker is an important step to further enable us to support our clients following drug approval,' said Gerhard Schmid, President of the Wacker Biosolutions business division.
'We will have access to know-how, highly qualified and experienced experts and a state-of-the-art, EMA-approved GMP manufacturing facility with a high production capacity.
'This is a milestone in the growth strategy of our biotechnology services and we look forward to a combined future.'
Ulrike Fiedler, CEO of Scil Proteins Production, added: 'With this transaction, the new company combines world-class know-how in E.coli refolding and secretion technologies and complementary manufacturing scales, which will bring value to our collective client base. We are confident that we have found the right partner to take the business forward and succeed in the future.'